Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
7.29
+0.19 (2.68%)
After Hours: 7.27 -0.02 (-0.27%)
Sep 2, 6:16PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.96 - 7.31
52 week 4.26 - 11.15
Open 7.22
Vol / Avg. 0.00/1.35M
Mkt cap 494.08M
P/E 131.83
Div/yield     -
EPS 0.06
Shares 69.68M
Beta 1.81
Inst. own 114%
Nov 5, 2015
Q3 2015 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 6, 2015
Q2 2015 Progenics Pharmaceuticals Inc Earnings Release
Aug 6, 2015
Q2 2015 Progenics Pharmaceuticals Inc Earnings Call - Webcast
Jul 8, 2015
Progenics Pharmaceuticals Inc at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 10, 2015
Progenics Pharmaceuticals Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -603.87% 9.94%
Operating margin -604.44% 7.59%
EBITD margin - 14.85%
Return on average assets -32.02% 3.20%
Return on average equity -42.50% 4.33%
Employees 57 -
CDP Score - -

Address

777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 62
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 58
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 50
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael D. Kishbauch Independent Director
Age: 66
Bio & Compensation  - Reuters
David A. Scheinberg MD., Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Nicole S. Williams Independent Director
Age: 70
Bio & Compensation  - Reuters